• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2016 Fiscal Year Final Research Report

Comprehensive analysis of resistance mechanism against ALK inhibitors and treatment strategy against such resistance mechanism

Research Project

  • PDF
Project/Area Number 15K18452
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Tumor therapeutics
Research InstitutionKyushu University

Principal Investigator

TOYOKAWA Gouji  九州大学, 医学研究院, 助教 (30627261)

Project Period (FY) 2015-04-01 – 2017-03-31
Keywords非小細胞肺癌 / ALK融合遺伝子 / ALK阻害剤 / 耐性機序
Outline of Final Research Achievements

Previous preclinical and clinical studies have identified various resistance mechanisms, such as secondary mutations in the ALK gene and the activation of bypass tracks. In the current study, novel ALK secondary mutations including I1171T/N and G1123S were shown to confer resistance against crizotinib, alectinib and ceritinib. Furthermore, we showed that MET amplification might mediate alectinib resistance, which could be overcome by crizotinib, a first generation ALK inhibitor. These findings are important for the optimal treatemnt strategies to overcome resistances against ALK inhibitors.

Free Research Field

胸部腫瘍学

URL: 

Published: 2018-03-22  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi